What is ziconotide approved for?

It is FDA-approved (as Prialt) for severe chronic pain in patients who need intrathecal therapy and are intolerant of or refractory to other treatments such as systemic analgesics or intrathecal morphine.

Is ziconotide an opioid?

No. It is a non-opioid analgesic with a different mechanism, so it does not cause respiratory depression or opioid-type dependence, but it has significant neuropsychiatric risks and a narrow therapeutic window.

FDA-approved medicineaka Prialt, omega-conotoxin MVIIA, SNX-111

Ziconotide — Complete Research Guide (2026)

Q: Does ziconotide have a boxed warning?

Yes. It carries an FDA boxed warning for severe psychiatric symptoms and neurological impairment, including cognitive impairment, hallucinations, mood changes, and risk of suicidal ideation; it should not be used in people with a history of psychosis.

Q: How is ziconotide given?

Only by intrathecal infusion into the cerebrospinal fluid via a specialized microinfusion pump, under pain-specialist supervision. It is never given orally or intravenously and cannot be self-administered.

Last updated 2026-07-31

TL;DR

A synthetic cone-snail venom peptide (N-type calcium-channel blocker), FDA-approved for severe chronic pain via intrathecal infusion; carries a boxed warning.

What is Ziconotide?

Ziconotide (brand name Prialt) is a synthetic 25-amino-acid peptide identical to omega-conotoxin MVIIA, a venom peptide from the cone snail Conus magus, and it acts as an N-type calcium channel blocker.

It is FDA-approved for severe chronic pain in patients requiring intrathecal (into the spinal fluid) therapy who are intolerant of or refractory to other treatments; it is delivered ONLY by intrathecal infusion pump, never orally or by IV.

Critically, it carries an FDA boxed warning for severe psychiatric symptoms and neurological impairment. Evidence is human and derives from randomized controlled trials (Staats, Rauck, Wallace).

How does Ziconotide work?

Ziconotide selectively blocks N-type voltage-gated calcium channels on primary nociceptive (pain-sensing) nerves in the dorsal horn of the spinal cord, preventing the calcium influx needed to release pain neurotransmitters.

This is a non-opioid mechanism, so it does not cause respiratory depression or tolerance in the way opioids do.

What does the research say about Ziconotide?

In refractory cancer or AIDS-related pain, intrathecal ziconotide produced significantly greater pain relief than placebo. ^[1]
In severe chronic pain, a slow-titration intrathecal ziconotide regimen improved pain scores versus placebo with better tolerability than faster titration. ^[2]
In chronic non-malignant pain, intrathecal ziconotide reduced pain versus placebo, though CNS side effects limited dosing. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial — Staats PS et al., JAMA 2004. (Randomized controlled trial)
[2] A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain — Rauck RL et al., Journal of Pain and Symptom Management 2006. (Randomized controlled trial)
[3] Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial — Wallace MS et al., Neuromodulation 2006. (Randomized controlled trial)
[4] Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics — Sanford M et al., CNS Drugs 2013. (Narrative/drug review)
[5] Ziconotide: a clinical update and pharmacologic review — Pope JE et al., Expert Opinion on Pharmacotherapy 2013. (Pharmacologic review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use ziconotide is started at a very low intrathecal dose and titrated slowly upward over days to weeks using an implanted or external microinfusion pump, under pain-specialist supervision with monitoring for cognitive and psychiatric effects.

This is regulatory and educational context only, not dosing guidance, and the intrathecal-only route means it cannot be self-administered.

Side effects & safety profile

Ziconotide carries an FDA boxed warning: it can cause severe psychiatric symptoms and neurological impairment, including cognitive impairment, hallucinations, decreased alertness/unresponsiveness, changes in mood or consciousness, and it can worsen depression with risk of suicidal ideation; patients with a history of psychosis should not receive it, and any emerging cognitive or neuropsychiatric signs should prompt dose reduction or discontinuation.

It has a narrow therapeutic window and requires slow titration and close monitoring, and it must be given ONLY intrathecally via an appropriate microinfusion device, never intravenously.

It is not addictive and causes no respiratory depression, but the neuropsychiatric risk profile makes specialist supervision mandatory.

Stacking & combinations

It may be used alongside intrathecal or systemic analgesics under specialist care, but combining it with other centrally acting agents can compound its neuropsychiatric and CNS depressant effects.

Finding Ziconotide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a synthetic copy of omega-conotoxin MVIIA, a peptide from the venom of the cone snail Conus magus, and it blocks N-type calcium channels to relieve pain.

References

[1] Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial — Staats PS et al., JAMA 2004. PMID: 14709577. View sourceStudy: Randomized controlled trialIntrathecal ziconotide significantly improved pain scores versus placebo in patients with refractory cancer or AIDS-related pain, with frequent neurological and psychiatric adverse effects.
[2] A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain — Rauck RL et al., Journal of Pain and Symptom Management 2006. PMID: 16716870. View sourceStudy: Randomized controlled trialA slower ziconotide titration schedule improved pain relief versus placebo in severe chronic pain while showing an improved tolerability profile compared with earlier rapid-titration studies.
[3] Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial — Wallace MS et al., Neuromodulation 2006. PMID: 22151630. View sourceStudy: Randomized controlled trialIntrathecal ziconotide reduced pain versus placebo in chronic non-malignant pain, but central nervous system adverse events were dose-limiting.
[4] Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics — Sanford M et al., CNS Drugs 2013. PMID: 23999971. View sourceStudy: Narrative/drug reviewReviews the efficacy and the narrow therapeutic window and neuropsychiatric adverse-effect profile of intrathecal ziconotide for refractory chronic pain.
[5] Ziconotide: a clinical update and pharmacologic review — Pope JE et al., Expert Opinion on Pharmacotherapy 2013. PMID: 23537340. View sourceStudy: Pharmacologic reviewSummarizes ziconotide's N-type calcium-channel mechanism, intrathecal-only administration, slow titration requirement, and boxed-warning neuropsychiatric risks.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.